Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Traws PharmaTRAW 40 EV-to-OCF is -0.19 as of Aug. 20, 2026. GuruFocus rates TRAW with a GF Score™ of 40/100 and a GF Value™ of $9.28 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Traws Pharma ranks worse than 71.19% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Traws Pharma's Enterprise Value is $3.28 Mil.
Traws Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-16.85 Mil. Therefore, Traws Pharma's EV-to-OCF for today is -0.19.
The historical rank and industry rank for Traws Pharma's EV-to-OCF or its related term are showing as below:
TRAW'
s EV-to-OCF Range Over the Past 10 Years
Min: -12.3 Med: 0.02 Max: 1.75
Current: -0.19
During the past 13 years, the highest EV-to-OCF of Traws Pharma was 1.75. The lowest was -12.30. And the median was 0.02.
TRAW's EV-to-OCF is ranked worse than 71.19% of 1409
companies
in the Biotechnology industry
Industry Median: -3.66
vs TRAW: -0.19
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Traws Pharma's PE Ratio (TTM) for today is calculated as:
Traws Pharma's share price for today is $0.54.
Traws Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Traws Pharma EV-to-OCF Related Terms
Traws Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Traws Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Traws Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Traws Pharma's EV-to-OCF falls into.
Traws Pharma's current Enterprise Value is $3.28 Mil.
Traws Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma (TRAW) has a EV-to-OCF of -0.19 as of Aug. 20, 2026. According to the industry distribution chart, Traws Pharma ranks #1003 out of 1409 companies in the Biotechnology industry, placing it in the top 71.2%.
Is Traws Pharma's EV-to-OCF too high?
Traws Pharma's current EV-to-OCF is -0.19. Based on the distribution chart, Traws Pharma ranks #1003 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Traws Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's EV-to-OCF compare to CNSP and MTVA?
According to the Biotechnology industry distribution chart, Traws Pharma ranks #1003 out of 1409 companies for EV-to-OCF. This places Traws Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Traws Pharma's current EV-to-OCF is -0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $9.28, compared to a current price of $0.54 — trading 94.2% below its estimated fair value. The current EV-to-OCF is -0.19. Traws Pharma's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Traws Pharma (TRAW), the current EV-to-OCF is -0.19 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Traws Pharma (TRAW) Overvalued in 2026?
Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued.
The current stock price of $0.54 is trading 94.2% below its estimated GF Value™ of $9.28.
GuruFocus considers Traws Pharma to be Possible Value Trap.
Key valuation signals for TRAW:
EV-to-OCF: -0.19
GF Value™: $9.28 vs. price of $0.54 (94.2% below fair value)
No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
40GF Score
Get the complete analysis for TRAW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRAW has been successfully added to your 
